Executive Publisher at Elsevier, publishing health-science journals in infectious disease in partnership with learned and professional associations.
Andrew Miller
Executive Publisher at Elsevier, publishing health-science journals in infectious disease in partnership with learned and professional associations.
| Abstract | Presenter | Abstract Title |
|---|---|---|
| 200 | Eftychia Eirini Maria Gourdoupari | Prognostic cut-off values of neutrofil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for COVID-19: a case-control retrospective single-center study |
| 584 | Şiran Keske | Insights from One of the Largest COVID-19 Cohorts: A Detailed Analysis of Risk Factors, Mortality Predictors, and Vaccine Efficacy in Istanbul |
| 145 | Arzuhan Buyuker | Evaluation of The Anti-Viral Response Against SARS-CoV-2 Omicron Variant Appeared In The First Half of 2024 in Healthcare Workers Using In Vitro Cell Culture Model |
| 539 | Eda Alp | Association of Hepatitis-B virus infection status with survival and treatment response in non-small cell lung cancer patients on anti-pd-1/pd-l1 therapy |
| 668 | Nida Özcan | Changes in Hepatitis C Virus Genotype Distribution in Diyarbakır from 2011 to 2020: The Impact of Migration and Epidemiological Trends |
| 348 | Abdul Mannan Mustafa | HIV through the mind of people unknowingly living among HIV patients; KAP study about HIV in slum area of Pakistan |
| 500 | Jonathan Nkalubo | Factors associated with readiness to start antiretroviral therapy (ART) among young people (15-24 years) at four HIV clinics in Mulago Hospital, Uganda |
| 625 | Elif Türkmen | Effectıveness Of Fecal Mıcrobıota Transplantatıon In Chıldren Wıth Inflammatory Bowel Dısease |
| 677 | Alfonso J. Rodriguez-Morales | Relationships between morbidity from Mpox and international tourism globally during 2022-2024 epidemics |
| Abstract | Presenter | Abstract Title |
|---|---|---|
| 581 | Evangelos J. Giamarellos Bourboulis | Clarithromycin adjunct treatment leads to substantial financial savings in community-acquired pneumonia: sub-analysis of the ACCESS trial |
| 367 | Luca Mezzadri | Comparison of meropenem-vaborbactam with ceftazidime-avibactam in the treatment of carbapenem-resistant Enterobacterales infections |
| 530 | Sohayeb Mohamed Ayoub | The Role of Students in Improving Patient Safety: An Integrative Approach |
| 649 | Nofri Rahmadika | Altered Interferon Responses in Tuberculosis Patients with Type II Diabetes: Implications for Increased Disease Susceptibility |
| 372 | Matthijs S Berends | Impact of Pre-Existing Comorbidities and Multimorbidities, Demography and Viral Variants on Post-Acute Sequelae of COVID-19 (‘Long COVID’) in Dutch Primary Care: A Retrospective Cohort Study |
| 470 | Meltem Ayaş | The investigation of the effectiveness of TK medium in determining primary anti-tuberculosis drug susceptibilities of Mycobacterium tuberculosis and a newly developed pyrazinamide susceptibility test |
| 303 | Emine Alp | The Effect of Training and Monitoring of Environmental Cleaning on The Rates of Intensive Care Unit Acquired Infections in A University Hospital |
| 623 | Reham Khedr | Successful management of pediatric patients with low-risk febrile neutropenia using a clinical care pathway in Egypt |
| 195 | Shinya Tsuzuki | Antimicrobial use for influenza-like illnesses in Nha Trang, Vietnam |
| Abstract | Presenter | Abstract Title |
|---|---|---|
| 182 | Reshma Silvester | A peek into hospital poo: Tracking pathogens and antimicrobial resistance |
| 298 | Shakeel Mowlaboccus | Genomic characterisation of vancomycin variable Enterococcus faecium causing bacteraemia in Australia |
| 364 | Huynh Ngoc Tram Vo | Genomic features of carbapenem-resistant Klebsiella pneumoniae isolated in French Polynesia and description of a novel transposon Tn7722 responsible for NDM-1 dissemination |
| 660 | Huda Ahmed | Distribution of Minimum Inhibitory Concentrations and Resistance-associated Gene Mutations in Multidrug-resistant Mycobacterium tuberculosis Strains from Southern Türkiye: Insights on Bedaquiline, Delamanid, and Linezolid |
| 79 | Igor Mokrousov | Genetics of mycobacterial adaptation to selective pressure of antituberculous compounds dissected at the in vitro and in vivo levels |
| 652 | Şevval Arduç Tok | Ceftazidim-avibactam susceptibility of carbapenemase producing enterobacterales in an oxa-48 endemic area |
| 386 | Neşe İnal | In-Vitro Antimicrobial Susceptibility Results of Brucella Species in Eastern Türkiye |
| 692 | Maryam Taghizadeh-Ghehi | Pattern of antibiotic use over two decades in Iran: a national level assessment based on WHO AWaRe classification from 2000 to 2019 |
| 191 | Tuba Sena Karacesme | Potential Drug Interactions With Antibiotics On Intensive Care Units: A Retrospective Cross-Sectional Study |
Organised by the ISAC Early Career Working Group
Join us at the ICC 2024 Early Career Scientist Workshop, an exciting and integral part of our conference, designed specifically to highlight and foster the growth of new talent in the field of antimicrobial chemotherapy. This year, we are thrilled to feature presentations from the ISAC/ICC awardees, representing a diverse range of countries and research backgrounds. These early career scientists have been recognised for their exceptional contributions and will share their innovative research findings with the global community. The workshop not only offers a unique opportunity for these emerging researchers to gain visibility but also provides a platform for all attendees to engage with cutting-edge science, discuss novel ideas, and build collaborative networks.
Organised in collaboration with Elsevier
In this session hosted by Elsevier and the ISAC journal Editors (Journal of Global Antimicrobial Resistance and International Journal of Antimicrobial Agents) you will learn about the journals’ publishing system from the author’s perspective. This will include a detailed breakdown of the steps from submission to publication as well as how best to respond to peer reviewer comments. Publishing a paper can often be a daunting experience, especially for junior researchers, and we hope this session equips you with the skills, the tips and tricks, and the confidence you need to disseminate your research in a journal.
Optimal antimicrobial therapy is essential for critically ill patients in the intensive care unit (ICU). This workshop will focus on important issues and strategies to enhance the effectiveness of antimicrobial therapy in critically ill patients. The topics that will be covered include the use of broad-spectrum antimicrobials and antimicrobial de-escalation in the ICU, as well as the value of clinical microbiology to guide decision making in the management of critically ill patients. This session is targeted at healthcare professionals working in intensive care, including clinicians, pharmacists, nurses, as well as researchers interested in improving patient outcomes through better antimicrobial stewardship and strategies.
Organised by the ISAC Infection Prevention & Control Working Group
In general, sustainability and environmental protection are global topics of upmost importance. After the recent COVID-19 pandemic, sustainability in regard to infection prevention and control measures within the healthcare setting finally got the needed attention. Unfortunately, efforts to protect our environment and those to protect our patients seem to clash at times, in part, due to the lack of data or knowledge. This session aims to elude this conflict and give an overview of what is presently known to achieve the best for both goals.
Description of the interactive session
The aim of this interactive session is to cover the basic aspects of antibiotic pharmacokinetics (PK) and pharmacodynamics (PD). Participants will be expected to play an active role in discussions.
Learning Outcomes:
To provide a basic understanding for the pharmacokinetic (PK) and pharmacodynamic (PD) properties of anti-infective drugs.
To introduce in vitro and in vivo modeling as a tool to interpret PK and PD of antimicrobials.
To highlight the importance of using PK/PD to optimize the antimicrobial treatment.
To facilitate the use of therapeutic drug monitoring to optimize antibiotic treatment in patients.
Target Audience
Infectious diseases physicians, pharmacists, intensivists, microbiologists, advanced nurse practitioners in the ICU, and researchers.
Don’t miss this unique opportunity to dive deep into the latest advancements in antimicrobial susceptibility testing guided by EUCAST (European Committee on Antimicrobial Susceptibility Testing) standards.
Why Attend?
✅ Learn cutting-edge techniques to ensure precise antimicrobial therapy
✅ Bridge the gap between laboratory results and clinical decision-making
✅ Master EUCAST guidelines to enhance patient outcomes
✅ Hands-on sessions with expert microbiologists and clinicians
This interactive session is designed for infectious disease specialists, microbiologists, pharmacologists and healthcare professionals eager to stay ahead in the fight against antimicrobial resistance.
Unlock the power to combat antimicrobial resistance with our cutting-edge Interactive Session, “Building an Antimicrobial Stewardship Programme”!
This isn’t just an interactive session—it’s your opportunity to lead the charge in transforming how antibiotics are used in your healthcare setting. Guided by top experts, you’ll gain actionable insights into developing a successful stewardship programme from the ground up. Learn to design strategies that reduce resistance, improve patient outcomes and ensure the responsible use of antimicrobials, all while staying ahead of global healthcare trends.
Elevate your expertise, make a real-world impact and be at the forefront of innovation in antimicrobial stewardship. This is your chance to be a changemaker—don’t miss out!
You are invited to a unique, very easy and transformative learning experience, one that will reshape how you view and address the pressing challenges of today. This smart, interactive session will introduce you to One Health, an innovative interdisciplinary approach that tackles some of the world’s most critical issues.
We will focus specifically on One Health and two major topics: zoonotic diseases and climate change. Traditionally, health improvement efforts have been centered around interventions for humans alone. However, as scientific research has advanced, it has become clear that we can only make lasting progress by addressing the interconnected health of humans, animals, and the environment. This holistic approach is essential if we are to combat challenges such as antimicrobial resistance, climate change, the rise of zoonotic diseases, food safety, and other global health crises.
Have you thought about the true drivers of climate change? Or the vital role the environment plays in the transmission of zoonotic diseases? These crucial issues will be explored in an engaging and dynamic way during “The One Health Workshop”.
To participate fully in this very easy learning experience, please ensure you have your “Gmail account” ready, along with a “QR & barcode scanner app” installed on your smartphone. This journey will not only deepen your understanding of One Health and its key elements but also serve as the foundation for a new chapter in your professional growth. Don’t miss this incredible opportunity—it’s time to embrace a smarter, more comprehensive approach to getting information.
Chair: Prof. Murat Akova
| TOPICS | EXPERTS |
| Welcoming and Introduction | Prof. Murat Akova
Chairman |
| Nosocomial Pneumonia & Early Antimicrobial Therapy | Prof. Önder Ergönül |
| Sepsis: Strategies for Rapid Diagnosis & Management | Prof. İlker Devrim |
| Panel Discussion (Q&A) |
Chair: Prof. Serhat Ünal
| Time | Session title | Presenter |
| 11:45–11:55 | Welcome and introduction | Serhat Ünal (Turkey) |
| 11:55–12:10 | Keeping an eye on AMR: applying surveillance data to clinical practice | Rafael Cantón (Spain) |
| 12:10–12:20 | Panel discussion | All |
| 12:20–12:35 | Using real-world data to drive treatment success | Vu Do (Vietnam) |
| 12:35–12:45 | Panel discussion | All |
| 12:45–13:00 | Optimising dosing to improve patient outcomes and manage AMR | Balaji Veeraraghavan (India) |
| 13:00–13:05 | Panel discussion | All |
| 13:05–13:15 | Concluding remarks | Serhat Ünal (Turkey) |
11:45-11:50
Opening (All)
11:50- 12:25
Advances in Management of Bacterial CAP- Prof Dr Evangelos Giamarellos-Bourboulis
12:25- 13:00
Influenza Vaccination: Protecting the Public and the Vulnerable- Prof Dr Mine Durusu Över
13:00- 13:15 Discussion and Q&A (All)
Co-Chaired by Meral Akcay-Alireza Mafi
| Time | Speakers | |
| 12:00-12:05 | Co-Chairs | Opening Remarks |
| 12:05- 12:30 | Dr. Meral Akcay | Influenza beyond flu! |
| 12:30-13:00 | Dr. Alireza Mafi | Protection beyond flu! |
| 13:00-13:30 | Discussion and Q&A Session | All |